Catalog No.
DHC36901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08887
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN88, SAR153191, CAS: 1189541-98-7
Clone ID
Sarilumab
Sarilumab use in severe SARS-CoV-2 pneumonia, PMID: 33043284
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study, PMID: 32620597
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial, PMID: 27856432
Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis, PMID: 29931592
Sarilumab, PMID: 31643297
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis, PMID: 30590833
Sarilumab, PMID: 29999974
Pharmaco-Immunomodulatory Therapy in COVID-19, PMID: 32696108
Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis, PMID: 29482351
A comprehensive review on sarilumab in COVID-19, PMID: 33161757
Sarilumab: patient-reported outcomes in rheumatoid arthritis, PMID: 30154675
Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial, PMID: 33164349
Sarilumab: First Global Approval, PMID: 28290137
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis, PMID: 28579757
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study, PMID: 25733246
Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters, PMID: 33314148
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial, PMID: 32907638
Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial, PMID: 32938496
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, PMID: 31969328
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate, PMID: 32726514
An Update on Current Therapeutic Drugs Treating COVID-19, PMID: 32395418
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis, PMID: 32343882
Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab, PMID: 31536783
Pharmacoeconomic Review Report: sarilumab (Kevzara) [Internet], PMID: 30489710
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes, PMID: 32264972
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis, PMID: 31055792
Crisaborole, Dupilumab, and Sarilumab, PMID: 28882252
Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis, PMID: 27464017
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan, PMID: 30894208
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses, PMID: 30886733
Potential therapeutic agents against COVID-19: What we know so far, PMID: 32243270
Treatment of SARS-CoV-2: How far have we reached?, PMID: 32336723
IL-6: Relevance for immunopathology of SARS-CoV-2, PMID: 32475759
Efficacy and safety of sarilumab in patients with active rheumatoid arthritis, PMID: 29492111
Clinical Review Report: sarilumab (Kevzara) [Internet], PMID: 30489709
A living WHO guideline on drugs for covid-19, PMID: 32887691
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up, PMID: 31312844
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, PMID: 28264816
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies, PMID: 32522251
Current status of potential therapeutic candidates for the COVID-19 crisis, PMID: 32334062
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy, PMID: 32784217
Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale, PMID: 30877216
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs, PMID: 31090044
Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof), PMID: 32561148
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PMID: 29882210
A review of sarilumab for the treatment of rheumatoid arthritis, PMID: 29043871
Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19, PMID: 32792288
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient, PMID: 30787625
Potential strategies for combating COVID-19, PMID: 32778950
Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis, PMID: 30589626
For research use only. Not for human or drug use.
